UNSPSC 51434603: Semotiadil

This classification denotes a calcium channel blocker, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DGN08QZ30G. European Medicines Agency schedules Semotiadil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10481MIG. Semotiadil generally arises in the molecular formula C29H32N2O6S.

UNSPSC 51434603 Semotiadil is a Commodity code for a specific pharmaceutical agent. State and local governments procure this medication primarily through emergency medical services programs and public health initiatives. Recent solicitations show direct procurement of branded pharmaceuticals and generic equivalents—typically in bulk quantities with firm expiration-date warranties and rapid delivery cycles. The City of Tampa's Fire Rescue program exemplifies this work: purchasing Advanced Life Support Medications including epinephrine, labetalol, adenosine, and diltiazem for emergency response. Issuing bodies include municipal fire departments, state health agencies, and cooperative purchasing alliances coordinating multi-jurisdictional procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represents a growing model, aggregating demand across state and local facilities in multiple states to leverage volume pricing and standardized wholesaler relationships.

Recent activity concentrates in Florida and Minnesota, with Texas state health agencies conducting preliminary market research. The City of Tampa issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications with response deadline April 8, 2026 and an estimated contract value of $40,000, requiring delivery within ten calendar days and a one-year term with renewal options; this solicitation included a 5 percent bid discount for Small Local Business Enterprise participation. MMCAP issued an RFP (S1070000015802) in January 2026 with response deadline March 26, 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, effective July 1, 2026, with a two-year initial term and multi-award potential. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, signaling potential larger-scale procurement development in that state.